by International Regulation for APIs Helps Improve Drug Standards
Active pharmaceutical ingredient (API) refers to the active component in a drug. In simple terms, API is part of any drug that produces the intended effects. Drugs are usually formed from several components. The API acts as the primary ingredient. Other ingredients are commonly called excipients, and these elements are required to be biologically innoxious, often forming a changeable fraction of the drug product. The procedure for optimizing and compositing this mixture of ingredients used in the medicine is referred to as formulation. Some drugs have multiple active APIs to treat various symptoms or act in complex ways. Most of the production of APIs has been carried out by the local pharmaceutical companies. However, in previous years, many businesses have opted to transfer manufacturing overseas to cut costs. The increasing demand for pharmaceutical drugs is expected to expand the global active pharmaceutical ingredients (API) market during the forecast period.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111813
Defectively produced and contaminated active ingredients have been associated with adverse health outcomes, extending to death, in several incidents over the past decades. Therefore, most nations across the globe are now regulating active ingredients. Regulating active ingredients can help improve the quality and safety of drugs for consumers, can extend the pharmaceutical drug supply system across the globe, and will bring the active pharmaceutical ingredients (API) market into line with its international regulatory partners. Moreover, producers use specific measures to determine the strength of API in each drug. The measure can vary extensively from one brand to another. Every brand might use different test techniques that can result in various strengths. Nevertheless, the growing incidents of chronic diseases are expected to increase the global demand for the active pharmaceutical ingredients (API) market.
Supply Chain Restrictions on China Hampered Global API Production
During the COVID-19 crisis, pharmaceutical companies are fighting with the prompt hurdles arising from the disruption in supply chains and the mandate to change business functioning. It was anticipated that if the COVID-19 pandemic continues for a medium/long span of time, it may impact the supply of active material and ingredients from the Asia Pacific with all the import and export of pharmaceuticals globally. The global reliance on China for APIs in various biologics and generic drugs was halted with the operations of the manufacturing as directed by the government. The closure of manufacturing in India and China led to a decline in the global supply of drugs when the demand was at an all-time high. This has led to several countries rolling out programs for domestic API production. Moreover, nations across the EU have reassessed their healthcare standards for tackling the virus and securing a constant inflow of API production.
As the end of this crisis approaches, many manufacturers of active pharmaceutical ingredients are returning their focus on their pre-COVID projects, especially in the essential drugs segment. Leading pharmaceutical businesses are adopting new business models and offering solutions based on key performance indicators by nation. Healthcare expenses of society and current COVID-19 crisis have driven pharmaceutical producers to realign their standards to provide to a large patient pool. However, the impact of coronavirus is anticipated to considerably decrease organizational income and capital expenditures, as the shock solidified various organizations. This is most likely to result in increased investment from API manufacturers for the production, marketing, and promotion of their products. Nevertheless, with rapid production and distribution of COVID-19 vaccines, the global trade is set to reduce its limits for the global active pharmaceutical ingredients (API) market.
Synthetic API Likely to Witness Higher Demand
An API process is linked to a series of operations that result in the development of an active pharmaceutical ingredient. Major procedures or steps in the API process may include multi-step drug synthesis and fermentation, purification, crystallization, drying, milling, packing, labeling, and testing. Some drugs treated similarly to an API may be a bulk-finished product. Moreover, active pharmaceutical ingredients in pediatric formulations have drawn significant attention from regulatory agencies across the world, due to safety concerns. In drug pipelines, small molecule drugs are trending in popularity presently. The small molecule drugs have the maximum number of regulatory approval, and the growing trend is anticipated to continue in the upcoming future. This is likely to benefit the active pharmaceutical ingredients (API) market.
The market share of synthetic API processes has surpassed the biological process. However, the biological API production is growing faster than the synthetic process during the projected timeline. In addition, factors such as increase in aging populations in most of the western world and prevalence of chronic disease are contributing to the growth of the active pharmaceutical ingredients (API) market. Bio-production is growing more widespread as a way to manufacture safer and more efficient drugs. Innovative and inventive methods for curing cancer, cystic fibrosis, asthma, blindness, and heart disease are increasing the demand for biological drugs. Bio-pharmaceuticals operate with the body to defend itself, while synthetic drugs often simply shield the consequences of a disease. Furthermore, in 2020, the cardiovascular segment accounted for a major share of the global active pharmaceutical ingredients (API) market.
Hypertension and cardiovascular diseases are common diseases and account for significant medical disability and deaths worldwide. The growing demand for pharmaceutical products to treat the increasing number of patients is proving propitious for the global active pharmaceutical ingredients (API) market during the forecast period.
Due to all the above-mentioned factors, the global active pharmaceutical ingredients (API) market is expected to reach the market value of US$ 331.3 Bn in 2031, expanding at a CAGR of 6.4% from 2021 to 2031.
Analysts’ Viewpoint
Rise in prevalence of diseases & disorders and growth in government & organizational investments to develop APIs are major contributors to the expansion of the global active pharmaceutical ingredients (API) market. In addition, advancements in research & technology on biological processes and small molecule APIs are expected to prove beneficial for the increasing market demand. Moreover, the demand for higher quality, cost-effective drugs across the supply chain is reshaping the active pharmaceutical ingredients (API) market. The focus of manufacturers on innovative and decisive measures is anticipating new strategic plans post COVID-19 era. However, the global active pharmaceutical ingredients (API) market is projected to recover from the pandemic losses and shocks over the next few years.
Active Pharmaceutical Ingredients (API) Market: Overview
An active pharmaceutical ingredient (API) is any substance or mixture of substances used in the finished pharmaceutical product (FPP) that is intended to provide pharmacological action or to otherwise have a direct impact in the diagnosis, remedy, mitigation, therapy, or prevention of disease, or to have a direct effect in repairing, correcting, or altering physiological functions in humans
The global active pharmaceutical ingredients (API) market has experienced significant growth in the last decade, due to increase in incidence of chronic diseases
Increase in Abbreviated New Drug Applications (ANDA) drives demand for active pharmaceutical ingredients (API). In order to market a generic drug, a company needs to file Abbreviated New Drug Application (ANDA). An ANDA approval implies that the generic drug is comparable to the original drug in terms of dosage form, strength, route of administration, quality, performance characteristics, and intended use.
However, companies cannot manufacture a drug unless the patent of a drug expires. Hence, as billion dollar drugs lose patents, other drug manufacturers grab the opportunity to manufacture low cost generics and file for ANDA to the U.S. FDA.
The pharmaceutical industry has suffered significantly due to patent expiry of blockbuster drugs in the past few years. Demand for low cost substitutes is high in low- and middle-income countries in Asia Pacific, Africa, and Latin America. This increases the number of API manufacturers, as pharmaceutical drug manufacturers did not have enough in-house capacity to meet the demand.
Currently, majority of API manufacturers is concentrated in Asia Pacific, primarily India, China, and Taiwan. Teva Active Pharmaceutical Ingredients (TAPI), Aurobindo, and Sun Pharma are the leading API manufacturers in the region.
Increase in incidence of chronic diseases drives the global active pharmaceutical ingredients (API) market. According to the International Diabetes Federation, in 2019, 463 million people across the world were diagnosed with diabetes. Moreover, the number of new cancer cases per year is expected to increase to 23.6 million by 2030. Apart from cancer, a number of other diseases have shown rise in prevalence rates. Rise in prevalence of cancer, cardiovascular diseases, and diabetes; surge in sedentary lifestyle; and increase in geriatric population are the key drivers of the active pharmaceutical ingredients (API) market.
Lung cancer is the leading cause of cancer deaths in Asia Pacific. China alone accounts for over 50% of all cancer cases in the region. Changes in lifestyle and socio-cultural factors are the leading causes of cervical cancer. Major countries affected by breast cancer in Asia Pacific are India, Thailand, and China.
Small molecule drugs account for major share of the current drug pipeline. Despite new biologic entities entering the market, small molecules are experiencing a surge in usage in the clinical pipeline. Maximum number of FDA approvals in the last decade have been for small molecule drugs, and the trend is likely to continue during the forecast period.
Market Segmentation: Active Pharmaceutical Ingredients (API) Market
In terms of manufacturer type, the global active pharmaceutical ingredients (API) market has been classified into in house manufacturing and contract manufacturing. The in house manufacturing segment is anticipated to dominate the global active pharmaceutical ingredients (API) market during the forecast period.
Based on drug type, the global active pharmaceutical ingredients (API) market has been categorized into branded or innovative prescription drugs, generic prescription drugs, and over-the-counter (OTC) drugs. The branded or innovative prescription drugs segment dominated the global active pharmaceutical ingredients (API) market in terms of revenue in 2020.
In terms of API type, the global active pharmaceutical ingredients (API) market has been divided into synthetic, biological, and plant extracts. The synthetic segment dominated the global active pharmaceutical ingredients (API) market in terms of revenue in 2020.
Based on application, the global active pharmaceutical ingredients (API) market has been segregated into anti-infective, cardiovascular, neurological, metabolic disorder, respiratory, oncology, and others. The cardiovascular segment dominated the global active pharmaceutical ingredients (API) market in terms of revenue in 2020.
In terms of end user, the global active pharmaceutical ingredients (API) market has been split into pharmaceutical & biotechnological industry, CROs, CMOs, and others. The pharmaceutical & biotechnological industry segment dominated the global active pharmaceutical ingredients (API) market in terms of revenue in 2020.
Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The report provides current and expected revenue (US$ Bn) for each of these segments from 2017 to 2031, considering 2020 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2021 to 2031, along with market size estimations.
Regional Overview: Active Pharmaceutical Ingredients (API) Market
In terms of region, the global active pharmaceutical ingredients (API) market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
The current and expected market revenue (US$ Bn) of these regional markets and their major countries have been provided in the report from 2017 to 2031, with their CAGRs from 2021 to 2031
The study also offers a list of recommendations, highlights, and useful insights of the global active pharmaceutical ingredients (API) market, which would help new companies willing to enter the market and existing companies to increase market shares and in the decision-making process
Major Players
The active pharmaceutical ingredients (API) market report concludes with the company profiles section, which includes key information about major players in the global active pharmaceutical ingredients (API) market
Leading players analyzed in the active pharmaceutical ingredients (API) market report include
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Pfizer, Inc.
- Novartis AG
- Mylan N.V.
- Lonza
- WuXi AppTec Co., Ltd.
- Piramal Pharma Solutions
- Hisun USA, Inc.
- Ipca Laboratories Ltd.
- AbbVie, Inc.
- Alembic Pharmaceuticals Limited
- BASF SE
- Biocon Ltd.
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Cambrex Corporation
- Dr. Reddy’s Laboratories Ltd.
- Eli Lilly and Company
- GlaxoSmithKline plc.
Each of these players has been profiled in the active pharmaceutical ingredients (API) market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments
Key Questions Answered in Active Pharmaceutical Ingredients (API) Market Report
- What is the sales/revenue generated by active pharmaceutical ingredients (API) across all regions during the forecast period?
- What are the opportunities in the global active pharmaceutical ingredients (API) market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which manufacturer type segment is expected to generate the highest revenue globally in 2031? Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?
Active Pharmaceutical Ingredients (API) Market – Segmentation
Manufacturer Type
- In House Manufacturing
- Contract Manufacturing
Drug Type
- Branded or Innovative Prescription Drugs
- Generic Prescription Drugs
- Over-the-counter (OTC) Drugs
API Type
- Synthetic
- Biological
- Plant Extracts
Application
- Anti-infective
- Cardiovascular
- Neurological
- Metabolic Disorder
- Respiratory
- Oncology
- Others
End User
- Pharmaceutical & Biotechnological Industry
- CROs
- CMOs
- Others
Region
- North America
- Europe
- Asia pacific
- Latin America
- Middle East & Africa
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111813/2900
